-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35

Benzinga·07/30/2026 17:43:16
Listen to the news
RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $30 to $35.